Charles River Laboratories
348 hedge funds and large institutions have $5.19B invested in Charles River Laboratories in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 129 increasing their positions, 122 reducing their positions, and 23 closing their positions.
126% more call options, than puts
Call options by funds: $4.48M | Put options by funds: $1.99M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 23
5% more funds holding
Funds holding: 333 → 348 (+15)
6% more repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 122
3% more capital invested
Capital invested by funds: $5.03B → $5.19B (+$165M)
2.82% less ownership
Funds ownership: 99.46% → 96.64% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$146M |
| 2 |
BlackRock
New York
|
+$31.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$30.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.4M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$192M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$76.8M |
| 3 |
Goldman Sachs
New York
|
-$42M |
| 4 |
Millennium Management
New York
|
-$35.8M |
| 5 |
APG Asset Management
Amsterdam,
Netherlands
|
-$15M |
CRL Hedge Fund Activity: Q2 2018 in Review
348 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2018, worth a combined $5.19B — up 3.3% from $5.03B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CRL positions and 23 closed out — a net gain of 18 holders — while 129 added to existing stakes and 122 trimmed.
The largest buyer was Fidelity International, adding an estimated $146M. The largest seller was Fidelity Investments, cutting an estimated $192M.
- 348 institutional investors held Charles River Laboratories (CRL) as of Q2 2018, up from 333 in Q1 2018.
- Funds reported $5.19B of Charles River Laboratories stock for Q2 2018, up 3.3% quarter-over-quarter.
- 41 funds opened new Charles River Laboratories positions in Q2 2018 and 23 closed out, a net change of +18 holders.
- The largest Charles River Laboratories buyer in Q2 2018 was Fidelity International, an estimated $146M added.
- The largest Charles River Laboratories seller in Q2 2018 was Fidelity Investments, an estimated $192M sold.
Based on aggregated 13F filings for Q2 2018.